Spotlight on our research at ESMO Congress 2024
10 Sep 2024
Friday 13 September marks the beginning of the ESMO Congress 2024. Researchers from the MRC Clinical Trials Unit at UCL and our partners will showcase the latest work from our prostate cancer clinical trials.
The ESMO Congress brings together oncologists, researchers, clinicians, and professionals from around the world to discuss the latest advancements in cancer research and treatment. This year’s event will take place from Friday 13 - Monday 16 September in Barcelona, Spain, and virtually.
Details of the presentations and posters featuring the STAMPEDE, PATCH, and STAMPEDE2 trials are summarised in the tables below. All times are local to Barcelona.
Oral presentations
| Date | Time (CEST) | Session title | Title | Speaker |
| Sunday 15 September | 15:40-15:50 | Proffered paper session: GU tumours, prostate |
1596O - Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials |
Emily Grist |
| Monday 16 September | 10:25-10:30 | Mini oral session: GU tumours, prostate |
LBA69 - Prostate cancer efficacy results from a randomised phase 3 evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer |
Ruth Langley |
| 10:45-10:50 |
LBA70 - Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE |
Silke Gillessen |
Posters
| Date | Poster title | Speaker |
| Sunday 15 September |
1656TiP - The STAMPEDE2 Niraparib-Abiraterone Acetate + Prednisolone trial: A Phase III, Randomised, Open Label Trial in Patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT) |
Sarah Howlett |
|
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Metastatic Prostate Cancer (mPC) Starting Androgen Deprivation Therapy (ADT) |
Minal Padden-Modi | |
|
1657TiP - The STAMPEDE2 Stereotactic Ablative Body Radiotherapy (SABR) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer (PC) Starting Androgen Deprivation Therapy (ADT) |
Hoda Abdel-Aty |
Further information: